Nephroblastoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Wilms' Tumor or Nephroblastoma is a rare malignant renal tumor that typically affects children, characterized by abnormal proliferation of cells that resemble embryonic kidney cells (metanephroma), leading to the term embryonal tumor. It mainly affects young children between the ages of 1 and 5 years, although it can occur before the age of 1 year or after the age of 8 years. Adult forms are very rare. The tumor is usually present as an abdominal mass, which is frequently unilateral. Other symptoms may include abdominal pain, hypertension, fever, hematuria, and anemia. The disease progresses rapidly, with regional dissemination in the retroperitoneal space, lymph nodes, vessels (renal vein and inferior vena cava), and the peritoneal cavity in cases of tumor effraction, with a high likelihood of metastases in the lungs and liver. Nephroblastoma is sporadic in 99% of cases, with 10% of these cases associated with congenital anomalies or specific syndromes. Genetic anomalies have been found in different chromosomal regions within the tumors. Familial forms are uncommon (1% of cases) and are transmitted in an autosomal dominant fashion. Differential diagnoses include other renal tumors in children, such as mesoblastic nephroma, clear cell sarcoma, neuroblastoma, rhabdoid tumors, and metanephric stromal tumors.
·
In most cases, the prognosis is favorable,
with a survival rate of over 90%. Approximately 800 cases are diagnosed yearly
in the USA, accounting for about 6% of cancer in children.
Thelansis’s “Nephroblastoma Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Nephroblastoma treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Nephroblastoma across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Nephroblastoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment